Lenvima for Differentiated Thyroid Cancer – Details


( Last Updated : October 5, 2016)
Generic Name:
Lenvatinib
Project Status:
Complete
Therapeutic Area:
Differentiated Thyroid Cancer
Manufacturer:
Eisai Limited
Brand Name:
Lenvima
Project Line:
Reimbursement Review
Project Number:
PC0080-000
NOC Date:

Details


Strength:
4mg and 10mg Capsules
Tumour Type:
Endocrine
Indications:
Differentiated Thyroid Cancer
Funding Request:
For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC
Review Status:
Complete
Sponsor:
Eisai Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.